Turning Point Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TPTX and buy or sell other stocks, ETFs, and their options commission-free!About TPTX
Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor.
CEOSandra Ramos-Alves
CEOSandra Ramos-Alves
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2013
Founded2013
Employees—
Employees—
TPTX Key Statistics
Market cap3.78B
Market cap3.78B
Price-Earnings ratio-11.01
Price-Earnings ratio-11.01
Dividend yield—
Dividend yield—
Average volume1.17M
Average volume1.17M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$82.20
52 Week high$82.20
52 Week low$23.77
52 Week low$23.77
Stock Snapshot
Turning Point Therapeutics(TPTX) stock is priced at $76.01, giving the company a market capitalization of 3.78B. It carries a P/E multiple of -11.01.
During the trading day, Turning Point Therapeutics(TPTX) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Turning Point Therapeutics(TPTX) stock has reached 0, versus its average volume of 1.17M.
Over the past 52 weeks, Turning Point Therapeutics(TPTX) stock has traded between a high of $82.20 and a low of $23.77.
Over the past 52 weeks, Turning Point Therapeutics(TPTX) stock has traded between a high of $82.20 and a low of $23.77.
People also own
Based on the portfolios of people who own TPTX. This list is generated using Robinhood data, and it’s not a recommendation.